Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Description

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.

Conditions

Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.

Phase II Multi-Institutional Study of Low-Dose (2Gy) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Condition
Bone Pain
Intervention / Treatment

-

Contacts and Locations

Duarte

City of Hope, Duarte, California, United States, 91010

Los Angeles

Los Angeles General Medical Center, Los Angeles, California, United States, 90033

Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033

Los Angeles

Cedars Sinai Medical Center, Los Angeles, California, United States, 90048

Atlanta

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States, 30322

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Minneapolis

University of Minnesota - Masonic Cancer Center, Minneapolis, Minnesota, United States, 55455

New York

Icahn School of Medicine at Mount Sinai, New York, New York, United States, 10029

Philadelphia

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologic diagnosis of multiple myeloma
  • * Painful bone metastasis (index lesion) that has a radiographic correlate
  • * Patient may have had any number of prior chemotherapy/immunotherapy regimens (changes to systemic therapy or use of bisphosphonates for 4 weeks before and after RT are allowed, but recording of these changes must be made so it can be accounted for)
  • * Eastern Cooperative Oncology Group (ECOG) 0-2
  • * Brief Pain Inventory (BPI) score \>= 2
  • * Ability to understand and the willingness to sign a written informed consent
  • * Patients will be ineligible if the index lesion has received prior radiation therapy or prior palliative surgery. Patients may have received prior palliative or primary radiotherapy or surgery to other parts of the body, as long as the index lesion was not in the prior radiation fields and has not received prior palliative surgery
  • * Patients will also be ineligible if there is pathologic fracture or impending fracture at the site of the index lesion or planned surgical fixation of the bone at the index lesion
  • * Patients with clinical or radiographic evidence of spinal cord or cauda equina compression/effacement from the index lesion, and/or with index lesions located at the skull base or orbital lesions
  • * Patients must not be pregnant

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Southern California,

Adam Garsa, MD, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

2026-03-11